

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):
August 10, 2021

CLEARPOINT NEURO, INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other jurisdiction
of incorporation)

001-34822
(Commission
File Number)

58-2394628
(I.R.S. Employer
Identification Number)

120 S. Sierra Ave., Suite 100
Solana Beach, California 92075
(Address of principal executive offices, zip code)

(949) 900-6833
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value per share	CLPT	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 10, 2021, ClearPoint Neuro, Inc. (the "Company") issued a press release announcing its financial performance for the second fiscal quarter ended June 30, 2021. A copy of the press release is furnished herewith as Exhibit 99.1.

The information in Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

On August 10, 2021, the Company posted an updated investor presentation to its website at <http://ir.stockpr.com/clearpointneuro/investor-presentations>. A copy of the investor presentation is being furnished herewith as Exhibit 99.2. The Company may use the investor presentation from time to time in conversations with analysts, investors and others.

The information in Item 7.01 of this Form 8-K, as well as Exhibit 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit 99.1 [Press Release dated August 10, 2021](#)

Exhibit 99.2 [Investor Presentation dated August 2021](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 10, 2021

CLEARPOINT NEURO, INC.

By: /s/ Danilo D'Alessandro
Danilo D'Alessandro
Chief Financial Officer



ClearPoint Neuro Reports Second Quarter 2021 Results Record Case Volume Supported Clinically During the Quarter

SOLANA BEACH, CA, August 10, 2021 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2021.

Second Quarter Highlights

- Reported revenue of \$3.4 million, a 38% year-over-year increase;
- Clinical team supported a record 249 cases, a 98% year-over-year increase;
- Increased biologics and drug delivery revenue to \$1.4 million, a 19% year-over-year increase;
- Added biologics and drug delivery relationships bringing current count of active partners to approximately 35 from approximately 30 in Q1 2021; and
- Announced FDA clearance of the SmartFrame Array and performed first human cases.

Business Outlook

- The Company continues to estimate total case volume supported to be in the range of 900 – 1000 for 2021; and
- The Company continues to estimate revenue to be between \$16.0 and \$17.5 million for 2021.

“The ClearPoint Neuro team enjoyed multiple significant successes in the 2021 second quarter, headlined by our record case volume result, which demonstrated a return to pre-pandemic levels a quarter ahead of schedule,” commented Joe Burnett, the Company’s President and Chief Executive Officer. “Also encouraging has been the resumption of clinical and pre-clinical activities by our biologics and drug delivery partners who have resumed lab-based activities and enrollment in human clinical trials, which we believe puts the regulatory pathway for their therapies back on track. We are currently working with more than 30 partners in the drug delivery space and expect to add additional partners in the second half of 2021. Further, our development and production teams remain on track for all the programs we announced in February, which keeps our planned timelines and key milestones on schedule. While we are monitoring the impact of the new Delta wave of COVID-19 cases, which has again started to put pressure on elective procedures at several customer sites as hospital ICU beds fill up, we believe our biologics and drug delivery business will make up for any potential impact in the second half and we continue to estimate that the range of cases supported by our clinical team will be in a range of 900 – 1000, and that our revenues will be in a range of \$16.0 - \$17.5 million for 2021.”

Financial Results – Quarter Ended June 30, 2021

Total revenue was \$3.4 million for the three months ended June 30, 2021, and \$2.5 million for the three months ended June 30, 2020, which represents an increase of \$0.9 million, or 38%.

Functional neurosurgery navigation revenue, which consists of disposable product commercial sales related to cases utilizing the ClearPoint system, increased 74% to \$1.9 million for the three months ended June 30, 2021, from \$1.1 million for the same period in 2020. This increase reflects the resumption in the three months ended June 30, 2021, of elective surgical procedures, which were postponed or cancelled during the three months ended June 30, 2020, due to the effects of the COVID-19 pandemic.

Biologics and drug delivery revenue, which includes sales of disposable products and services related to customer-sponsored clinical trials utilizing our products, increased 19% to \$1.4 million for the three months ended June 30, 2021, from \$1.2 million for the same period in 2020. This increase was due to an increase, during the quarter ended June 30, 2021, relative to the same period in 2020, in biologic and drug delivery service revenue of \$0.2 million, and an increase in biologic and drug delivery product revenue of \$0.04 million.

Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software, and of related services, were \$0.2 million for each of the three months ended June 30, 2021. Revenue from this product line historically has varied from quarter to quarter, and overall, the Company believes that hospitals’ capital equipment acquisition activities remain at a low level, relative to the acquisition activity prior to the onset in 2020 of the COVID-19 pandemic.

Gross margin for the three months ended June 30, 2021, was 67%, as compared with gross margin of 68% for the same period in 2020. This decrease in gross margin was due primarily to a decreased contribution, during the three months ended June 30, 2021, as compared to the same period in 2020, from service revenue, which carries a higher gross margin relative to product lines, substantially offset by an increased contribution from functional

neurosurgery navigation disposable product sales, which carry a higher gross margin relative to other product lines.

Research and development costs were \$2.1 million for the three months ended June 30, 2021, compared to \$0.8 million for the same period in 2020, an increase of \$1.3 million, or 161%. The increase was due primarily to increases in personnel costs due to growth in headcount, and software development and product development costs. Sales and marketing expenses were \$1.6 million for the three months ended June 30, 2021, compared to \$1.1 million for the same period in 2020, an increase of \$0.5 million, or 42%. This increase was due primarily to increases in marketing personnel costs resulting from increases in headcount, and a commensurate increase in marketing activities including our expansion into Europe. General and administrative expenses were \$2.0 million for the three months ended June 30, 2021, compared to \$1.2 million for the same period in 2020, an increase of \$0.8 million, or 63%. This increase was due primarily to increases in state franchise taxes, share-based compensation, occupancy costs, insurance and professional fees related primarily to public company reporting.

At June 30, 2021, the Company had cash and cash equivalents totaling \$61.5 million as compared to \$20.1 million at December 31, 2020, with the increase resulting primarily from the completion of a public offering of its common stock in February 2021.

Teleconference Information

Investors and analysts are invited to listen to a live broadcast review of the Company's 2021 second quarter on Tuesday, August 10, 2021 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed [online here](#). Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada and then entering conference I.D. number 13721705.

For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until September 10, 2021, by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's website at www.clearpointneuro.com, on the "Investor Relations" page.

About ClearPoint Neuro

ClearPoint Neuro's mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company's current product portfolio include deep brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint® Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro is partnered with approximately 35 biologics/pharmaceutical companies and academic centers, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 4,500 cases have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners. For more information, please visit www.clearpointneuro.com.

Forward-Looking Statements

Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of the COVID-19 pandemic and the measures adopted to contain its spread; future revenue from sales of the Company's ClearPoint Neuro Navigation System products; the Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation System products; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2021, both of which has been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2021, which the Company intends to file with the Securities and Exchange Commission on or before August 16, 2021.

Contact:

Danilo D'Alessandro, Chief Financial Officer
(949) 900-6833
info@clearpointneuro.com

Caroline Corner, Investor Relations
ir@clearpointneuro.com

		For The Three Months Ended June 30,	
		2021	2020
Revenue:			
Product revenue	\$	2,363	\$ 1,636
Service and other revenue		1,050	842
Total revenue		3,413	2,478
Cost of revenue		1,123	802
Gross profit		2,290	1,676
Research and development costs		2,123	812
Sales and marketing expenses		1,592	1,125
General and administrative expenses		1,982	1,214
Operating loss		(3,407)	(1,475)
Other expense:			
Other (expense) income, net		(96)	11
Interest expense, net		(240)	(197)
Net loss	\$	(3,743)	\$ (1,661)
Net loss per share attributable to common stockholders:			
Basic and diluted	\$	(0.17)	\$ (0.11)
Weighted average shares used in computing net loss per share:			
Basic and diluted		21,523,393	15,504,169
		For The Six Months Ended June 30,	
		2021	2020
Revenues:			
Product revenues	\$	5,525	\$ 3,814
Service and other revenues		1,918	1,779
Total revenues		7,443	5,593
Cost of revenues		2,539	1,733
Gross profit		4,904	3,860
Research and development costs		3,687	1,631
Sales and marketing expenses		3,167	2,423
General and administrative expenses		3,638	2,490
Operating loss		(5,588)	(2,684)
Other income (expense):			
Other (expense) income, net		(122)	6
Interest expense, net		(571)	(1,038)
Net loss	\$	(6,281)	\$ (3,716)
Net loss per share attributable to common stockholders:			
Basic and diluted	\$	(0.31)	\$ (0.24)
Weighted average shares used in computing net loss per share:			
Basic and diluted		20,195,488	15,471,222

CLEARPOINT NEURO, INC.
Consolidated Balance Sheets
(Dollars in thousands, except for per share data)

		June 30, 2021 (Unaudited)	December 31, 2020
ASSETS			
Current assets:			
Cash and cash equivalents	\$	61,524	\$ 20,099
Accounts receivable, net		2,407	1,881
Inventory, net		3,575	3,238
Prepaid expenses and other current assets		1,003	244
Total current assets		68,509	25,462
Property and equipment, net		349	319
Operating lease rights of use		2,489	2,736
Software license inventory		519	589
Licensing rights		309	353
Other assets		151	59
Total assets	\$	72,326	\$ 29,518
LIABILITIES AND STOCKHOLDERS' EQUITY			
Current liabilities:			
Accounts payable	\$	1,252	\$ 300
Accrued compensation		1,411	1,595
Other accrued liabilities		892	349
Operating lease liabilities, current portion		462	394
Deferred product and service revenue		368	562
Total current liabilities		4,385	3,200

Operating lease liabilities, net of current portion	2,203	2,446
Deferred product and service revenue, net of current portion	268	215
2020 senior secured convertible notes payable, net	17,504	21,280
Total liabilities	24,360	27,141
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$0.01 par value; 25,000,000 shares authorized; none issued and outstanding at June 30, 2021 and December 31, 2020	—	—
Common stock, \$0.01 par value; 200,000,000 shares authorized; 22,322,344 shares issued and outstanding at June 30, 2021; and 17,047,584 issued and outstanding at December 31, 2020	223	170
Additional paid-in capital	173,546	121,729
Accumulated deficit	(125,803)	(119,522)
Total stockholders' equity	47,966	2,377
Total liabilities and stockholders' equity	\$ 72,326	\$ 29,518

CLEARPOINT NEURO, INC.
Consolidated Statements of Cash Flows
(Dollars in thousands)

	For The Six Months Ended June 30,	
	2021	2020
Cash flows from operating activities:		
Net loss	\$ (6,281)	\$ (3,716)
Adjustments to reconcile net loss to net cash flows from operating activities:		
Allowance for doubtful accounts	92	2
Depreciation and amortization	62	116
Share-based compensation	567	469
Payment-in-kind interest	189	—
Amortization of debt issuance costs and original issue discounts	54	821
Amortization of lease rights of use, net of accretion in lease liabilities	267	50
Increase (decrease) in cash resulting from changes in:		
Accounts receivable	(617)	(76)
Inventory, net	(304)	(313)
Prepaid expenses and other current assets	(760)	(181)
Other assets	(93)	70
Accounts payable and accrued expenses	1,312	93
Accrued interest	—	(960)
Lease liabilities	(195)	(48)
Deferred revenue	(142)	(366)
Net cash flows from operating activities	(5,849)	(4,039)
Cash flows from investing activities:		
Purchases of property and equipment	(5)	—
Acquisition of licensing rights	—	(441)
Net cash flows from investing activities	(5)	(441)
Cash flows from financing activities:		
Proceeds from issuance of 2020 senior secured convertible notes, net of financing costs and discount	—	16,758
Proceeds from issuance of Paycheck Protection Program loan	—	896
Proceeds from public offering of common stock, net of offering costs	46,785	—
Proceeds from stock option and warrant exercises	494	—
Repayment of notes payable	—	(2,838)
Net cash flows from financing activities	47,279	14,816
Net change in cash and cash equivalents	41,425	10,336
Cash and cash equivalents, beginning of period	20,099	5,696
Cash and cash equivalents, end of period	\$ 61,524	\$ 16,032

SUPPLEMENTAL CASH FLOW INFORMATION

Cash paid for:		
Income taxes	\$ —	\$ —
Interest	\$ 353	\$ 1,043



WHEN YOUR PATH IS UNCLEAR,
WE POINT THE WAY.™

Nasdaq: CLPT


August 2021



FORWARD LOOKING STATEMENTS

Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: the impact of COVID-19 and the measures adopted to contain its spread; future revenues from sales of the Company's ClearPoint Neuro Navigation System products; the Company's ability to market, commercialize and achieve broader market acceptance for the Company's ClearPoint Neuro Navigation System products; and risks inherent in the research and development of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and the Company's Quarterly Report on Form 10-Q for the three months ended March 31, 2021, both of which have been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2021, which the Company intends to file with the Securities and Exchange Commission on or before August 16, 2021.

ClearPoint Neuro: Two Opportunities, One Platform



A Biologics & Drug Delivery Company with a Broad Portfolio of Pharma Partners and Indications with Potentially Explosive Growth

- \$1B+ Potential Market, first indication expected in 2022
- 2020 Growth of 109% during COVID

A Medical Device Company with an Innovative and Expanding Portfolio Supported by an Established On-Site Clinical Channel

- \$500M+ in Existing Market Opportunity
- 5+ New Products Expected in next 2 Years

ClearPoint Neuro: A Proven Platform

Key Products: **FDA CE** Marked Platforms

HEADQUARTERS
Solana Beach, CA

2020 REVENUE
\$12.8m

U.S. PATENTS ISSUED
65

EMPLOYEES
70+
30+ field
37+ production & development

MANUFACTURING
Irvine, CA

CASH
\$61.5m^(A)

GROSS MARGIN
67%^(A)

EUROPEAN HEADQUARTERS
Manchester, UK



**Razor / Razorblade
model with 85+ % of
revenue from single-
use disposables and
services**



(A) As of, and for the quarter ended, June 30, 2021


Limitations of Traditional Stereotactic Neurosurgery Lack of Real-Time Image Guidance

PRIMARY CHALLENGE

For minimally invasive procedures to be successful, the surgeon needs imaging to see into the head

MRI is the best imaging tool for the brain

Large, metallic frames are not MRI compatible



Video source: <https://www.youtube.com/watch?v=PsL9B7fbG4>




Big Iron companies like Siemens and Philips are innovating to make interoperative MRI scanners more accessible



© 2021 CLEARPOINT NEURO

5

Our Platform – Procedure Overview The ClearPoint® Neuro Navigation System





Leverage live MR Imaging to **Decide, Guide, Treat and Confirm** with sub-millimetric accuracy.



© 2021 CLEARPOINT NEURO

6

SmartFrame® XG





SmartFrame XG Trajectory Tower
with ClearPoint 2.0 Software



*The SmartFrame Array Tower, Software and Robotic System are currently under development.

SmartFrame Array™




SmartFrame Array Tower*
with “virtual array” Software and next generation
robotic system with increased automation and
enabling software


© 2021 CLEARPOINT NEURO | 7

The ClearPoint ‘Maestro’ Brain Model* Licensed and Jointly Developed with Philips

1. Shape Constrained, triangular mesh model enables point-based correspondence across multiple subjects
2. Fast and capable of peri-procedural imaging without CPU acceleration
3. This model is the basis for future navigation tools across Biologics & Drug Delivery, DBS Navigation, Laser Ablation and more.



*The ClearPoint Maestro™ Brain Model is currently under development.



© 2021 CLEARPOINT NEURO | 8

Our MRI-guided therapy platform
is currently being used to...

CLPT PLATFORM RUNS
ON ALL MAJOR SCANNERS

DELIVER BIOLOGICS
AND DRUGS

IMPLANT NEURO
STIMULATION LEADS

PLACE LASER
ABLATION PROBES

SIEMENS



PHILIPS

IMRIS

PTC
THERAPEUTICS

SIO
GENE THERAPIES

BlueRock
Therapeutics

LYSOGENE

uniQure

charles river

...with ~35 commercial
and academic partners

Medtronic

Abbott

**Boston
Scientific**

NEUROPACE

Medtronic
VISUALASE

MONTERIS
MEDICAL

CLEARPOINT
NEURO

© 2021 CLEARPOINT NEURO | 9

Broad and Growing User Base of Leading Neurosurgery Centers

60+ Centers in the US, Canada and EU... and Growing Globally

UC San Francisco
Stanford University
UCSF Children's Hospital
UCSF Benioff Children's
San Francisco VA
USC Keck Hospital
UC San Diego
Mayo Clinic Phoenix
University of Colorado
University of Utah
University of Arizona
Banner Health Tucson
Cook Children's Hospital
Texas Children's Hospital
MD Anderson Cancer Center
Houston Methodist Hospital
Univ. Kansas Medical Center
Dallas Presbyterian Hospital
Willis-Knighton
Oklahoma State University
Cincinnati Jewish
Children's National

University of Wisconsin
University of Michigan
University of Minnesota
Cincinnati Children's Hospital
Ohio State University
Cleveland Clinic
Northwestern Central DuPage
Nationwide Children's

Charles River Labs (Laval, Canada)
Children's Mercy Hospital
CHOA Scottish Rite
Le Bonheur
INOVA Fairfax
Carilion Clinic
Hos. Univ. of Pennsylvania
UPMC

Rigshospitalet (Copenhagen, Denmark)
Mazowiecki Szpital Bródnowski (Warsaw, Poland)
Hôpital Fondation Rothschild (Paris, France)
Johns Hopkins University
Yale University
Boston Children's Hospital
Weill Cornell
Brigham & Women's
Massachusetts General Hospital
National Institutes of Health
Memorial Sloan-Kettering
Dartmouth-Hitchcock
Mt. Sinai West
Beth Israel Deaconess
Children's of Philadelphia
Hackensack Univ. Med. Center
University of Virginia
Children's of Alabama
Duke University
Tampa General Hospital
Mayo Clinic in Florida
Emory University

100+
Centers
Expected
by 2025

CLEARPOINT
NEURO

10


Biologics & Drug Delivery

1. Biologics & Drug Delivery Why ClearPoint?

Benefits of ClearPoint

1. Select and confirm the most accurate trajectory before insertion using live MRI Guidance
2. Identify peri-procedural safety issues live instead of after the patient is closed (i.e., hemorrhage)
3. Confirm proper target coverage with drug before closing the patient


***Every Clinical Trial Patient is Crucial.
Why Take Any Chances?***



Only ClearPoint combines real-time direct imaging software and hardware to allow intra-procedural adjustment by the Neurosurgeon


1. Biologics & Drug Delivery

Estimated \$1.5B* Market Opportunity As Platform for Gene Therapy



1. Biologics & Drug Delivery


Specialized Consultation for Pharmaceutical Customers



Navigation Device & Therapy

2. Neuro Navigation (DBS) Deep Brain Stimulation

Deep brain stimulation (DBS) uses a surgically implanted medical device, similar to a cardiac pacemaker, and leads to deliver controlled electrical stimulation to precise targeted areas in the brain.



The ClearPoint® Neuro Navigation Platform is used to accurately place leads in the appropriate targeted structure. The leads are connected in a separate procedure to a neurostimulator implanted near the collarbone.

2. Neuro Navigation (DBS)

Deep Brain Stimulation

Gaining Share in a Growing Market




Boston
Scientific

Medtronic

Abbott

NEUROPACE

Parkinson's Patient Population (US)



Total Current Addressable U.S. Market

6,000 x \$12,000 / case = \$72M
(Navigation & MER)

Growing 10%

CLEARPOINT
NEURO

© 2021 CLEARPOINT NEURO | 17

2. Neuro Navigation (DBS)

Improved Navigation & Technology, New Indications Drive DBS Market Growth of 10%+ CAGR 2020-2025

New Indications in Trials	Treatment Populations	Neurosurgical Targets	Pilot	Phase I/II	Phase III	Commercial
Epilepsy ¹	2 million+	Multiple				
Obsessive Compulsive Disorder (OCD) ²	10 million+	Ventral internal capsule/ventral striatum (V CVS)				
Alzheimer's Disease ³	6 million+	Fornix				
Severe Depression ⁴	10 million+	Multiple				
Early Parkinson's ⁵	2 million+	Multiple				
Stroke Rehabilitation ⁶	2 million+	Dentate nucleus				
Insomnia ⁷	1 million+	External and internal segments of the globus pallidus (GPe/Gpi)				

CLEARPOINT
NEURO


¹ <https://www.cdc.gov/epilepsy/about/fast-facts.htm>; ² <https://adaa.org/about-adaa/press-room/facts-statistics>; ³ <https://dshs.texas.gov/alzheimers/default.aspx>; ⁴ <https://adaa.org/about-adaa/press-room/facts-statistics>; ⁵ <https://parkinsonsnewstoday.com/parkinsons-disease-statistics/>; ⁶ <https://www.cdc.gov/stroke/facts.htm>; ⁷ <https://www.mayoclinicproceedings.org/action/showPdf?pii=S0025-6196%2819%2931034-1>

© 2021 CLEARPOINT NEURO | 18

3. New Therapy Devices

ClearPoint Neuro Laser Therapy – Capturing the Entire Procedure

LITT uses laser energy to destroy unwanted cells




- Today MRI is required during LITT procedures to precisely monitor and control the temperature and thermal dose from that laser.
- ClearPoint is chosen by Neurosurgeons for the most difficult Neuro LITT cases today.
- One clinical support team and a simplified iMRI workflow will accelerate growth.
- ClearPoint has partnered with CLS and IGT to develop an optimized laser and thermometry system to capture the entire procedure.




INFLEXION™ Head Fixation Frame

ClearPoint Compatibility Kits



TRANBERG® Laser



Innovative laser fiber technology designed to optimize heat distribution, eliminate external cooling, and help reduce procedure times. FDA cleared, CE Marked for non-neuro applications.

3. New Therapy Devices


ClearPoint Neuro Laser Therapy* – Capturing the Entire Procedure

Significant Addressable Neuro Market in Epilepsy and Tumor


Medtronic

MONTERIS
MEDICAL


LITT for Epilepsy - Total Addressable Patient Population (US)



LITT for Tumors - Total Addressable Patient Population (US)



Navigation
(\$6,000)




Laser
Applicators
(\$12,000)

Total Current Addressable Market
 $20,000 \times \$18,000 / \text{case} = \360M
(Navigation & Laser Applicators)

2020
1,200
Actual LITT
Procedures
Today (est)
ClearPoint
used in
30%

Growing 20+%

ClearPoint Cove Training and Innovation Center – Solana Beach, CA



- Intimate training experience for surgeons and staff to perform mock procedures and provide pipeline feedback
- Showcase new technology for Pharmaceutical Drug Delivery partners
- Home for remote support specialists to reduce travel for simpler procedures




















© 2021 CLEARPOINT NEURO

21

Innovation

Accelerated Product Pipeline and Target First Clinical Use

	2020-21	2022	2023
Navigation & Robotics	 <p>Inflexion™ Head Fixation Frame</p>  <p>SmartFrame Array™¹</p>	 <p>ClearPoint Neuro Navigation Software v. 2.1²</p>  <p>ClearPoint Maestro™ Brain Model²</p>	 <p>ClearPoint Maestro™ Sub Nuclei App²</p>  <p>ClearPoint Revolution™ Robotic Navigation System²</p>
Biologics & Drug Delivery	 <p>Pre-Clinical & Clinical Support Services</p>	 <p>Pre-Clinical Head Fixation Frame²</p>  <p>ClearPoint Maestro™ Infusion Modeling App²</p>	 <p>Orchestra™ Head Fixation Frame²</p>  <p>ClearPoint Maestro™ Infusion Targeting App²</p>
Therapy and Enabling Technology	 <p>5F and 7F Peel-Away Sheath Kits</p>  <p>Bladed Lancet</p>	 <p>Laser Ablation System w/ ThermoGuide²</p>  <p>Biopsy Needle²</p>	 <p>Micro-Electric Recording System (MER)²</p>  <p>"Smart" Biopsy Needle²</p>

CLEARPOINT
NEURO

1. 510(k) cleared, pending CE Mark. Not commercially available in all countries.


2. Currently under development and not yet commercially available. Future availability cannot be guaranteed.

© 2021 CLEARPOINT NEURO

22

4 Pillar Growth Strategy by 2025



Target Indications of > 150,000 procedures per year represents
Potential Addressable Market for CLPT of \$1B+



Financials

2013 - 2021

Growth in Case Volume and Revenue



CLPT CAPABILITIES

Executive Summary



Unique Platform technology

enabling Precision MRI-Guided Therapies to restore quality of life for some of the most debilitating disorders



Pipeline of new revenue streams

from product improvements, biologic and drug delivery partnerships, and standalone therapy products



Procedure volume has grown

33%+ CAGR from 2013-2019



Total potential addressable market

> \$1B for our products and pipeline



Large, Growing installed

base in 60+ of 250+ leading Neurology clinical and research centers in U.S., Canada and Europe



A passionate team

of embedded scientists and specialists

